Cost-effectiveness of first-line antiepileptic drug treatments in the developing world: A population-level analysis

Epilepsia

Volumn 46, Issue 5, 2005, Pages 751-759

  Chisholm, Dan ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Antiepileptic drugs; Cost effectiveness; Costs; DALYs

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ANTICONVULSANT THERAPY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; EPILEPSY; HEALTH CARE DELIVERY; HUMAN; IDIOPATHIC DISEASE; INTERNATIONAL COOPERATION; POPULATION MODEL; PRIMARY HEALTH CARE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PUBLIC HEALTH; TREATMENT OUTCOME; TREATMENT PLANNING; WORLD HEALTH ORGANIZATION;

ANTICONVULSANTS; COST-BENEFIT ANALYSIS; CROSS-CULTURAL COMPARISON; DEVELOPED COUNTRIES; DRUG COSTS; EPILEPSY; HEALTH CARE COSTS; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MEDICALLY UNDERSERVED AREA; PRIMARY HEALTH CARE; PROBABILITY; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 18244405045     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2005.52704.x     Document Type: Article

References (40)

1. World Health Organization. The World Health Report 2001; Mental Health: New Understanding, New Hope. 2001; WHO, Geneva.
2. Meinardi H, Scott RA, Reis R, Sander JW, on behalf of the ILAE Commission on the Developing World. The treatment gap in epilepsy: The current situation and ways forward. Epilepsia 2001;42:136-149.
3. Begley CE, Famulari A, Annegers JF, et al. The cost of epilepsy in the United States: an estimate from population-based and survey data. Epilepsia 2000;41:342-352.
4. Cockerell OC, Hart YM, Sander JWAS et al. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy Research 1994;18:249-260.
5. Thomas SV, Sarma PS, Alexander M, Pandit L, Shekhar L, Trivedi C, Vengamma B. Economic burden of epilepsy in India. Epilepsia 2001;42:1052-1060.
6. Kleinman A, Wang WZ, Li SC, et al. The social course of epilepsy: chronic illness as social experience in interior China. Soc Sci Med 1995;40:1319-30.
7. Heaney DC, Begley CE. Economic evaluation of epilepsy treatment: a review of the literature. Epilepsia 2002;43(suppl 4):10-7.
8. Hutubessy R, Chisholm D, Tan Torres T. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector: cost effectiveness and resource allocation 2003;1:8. [http://www.resource-allocation. com/content/1/1/8]
9. Sander JW. The use of antiepileptic drugs: principles and procedures. Epilepsia 2004;45(suppl 6):28-34.
10. Begley CE, Beghi E, Beran RG, et al. ILAE Commission on the burden of epilepsy: subcommission on the economic burden of epilepsy: final report 1998-2001. Epilepsia 2002;43:668-73.
11. Tan Torres T, Baltussen RM, Adam T. et al. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization, 2003.
12. Lauer JA, Murray CJL, Roehrich K, et al. PopMod: a longitudinal population model with two interacting disease states: cost effectiveness and resource allocation. 2003;1:6. [http://www.resource-allocation.com/content/1/1/ 6]
13. Leonardi M, Ustun B. The global burden of epilepsy. Epilepsia 2002;43(suppl 6):21-5.
14. World Health Organization. International Statistical Classification of Diseases and Related Health Problems. 10th Revision. Geneva: World Health Organization, 1992.
15. Annegers JF. Mortality. In Engel J, Pedley TA, eds. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven, 1997:99-104.
16. Cockerell OC, Johnson AL, Sander JWAS, et al. Mortality from epilepsy: results from a prospective population-based study. Lancet 1994;344:918-21.
17. Cockerell OC, Johnson AL, Sander JWAS, et al. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet 1995;346:140-4.
18. Annegers JF, Hauser WA, Elveback LR. Remission of seizures and relapse in patients with epilepsy. Epilepsia 1979;20:729-37.
19. Hauser WA, Kurland LT. The epidemiology of epilepsy in Rochester Minnesota, 1935 through 1967. Epilepsia 1975;16:1-66.
20. Mani KS, Rangan G, Srinivas HV, et al. Natural history of untreated epilepsy: a community-based study in rural South India. Epilepsia 1993;34(suppl 2):166.
21. Zielínski JJ. Epileptics not in treatment. Epilepsia 1974;15:203-10.
22. Murray CJL, Lopez AD. The global burden of diseases: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Boston: Harvard School of Public Health, WHO and World Bank, 1996.
23. Placencia M, Sander JWAS, Roman M, et al. The characteristics of epilepsy in a largely untreated population in rural Ecuador. J Neurol Neurosurg Psychiatry 1994;57:320-5.
24. Kwan P, Brodie M. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-9.
25. Sander JWAS. Some aspects of prognosis in the epilepsies: a review. Epilepsia 1993;34:1007-16.
26. Johns B, Baltussen R, Adam T, et al. Programme costs in the economic evaluation of health interventions, cost-effectiveness and resource allocation. 2003;1:1. [http://www.resource-allocation.com/content/1/1/1]
27. Ferri C, Chisholm D, van Ommeren M, et al. Resource utilisation for neuropsychiatric disorders in developing countries: a multinational Delphi consensus study. Soc Psychiatry Psychiatric Epidemiol 2004;39:218-27.
28. Adam T, Evans D, Murray CJ. Econometric estimation of country-specific hospital costs: cost-effectiveness and resource allocation 2003;1:3. [http://www.resource-allocation.com/content/1/1/3]
29. Institute of Medicine. Neurological, psychiatric and developmental disorders: meeting the challenge in the developing world. Washington, DC: National Academy Press, 2001.
30. World Health Organization. Macroeconomics and health: investing in health for economic development. Geneva: WHO, 2001.
31. Chisholm D, Sanderson K, Ayuso-Mateos JL, et al. Reducing the global burden of depression: population-level analysis of intervention cost-effectiveness in 14 world regions. Br J Psychiatry 2004;184:393-403.
32. Murray CJ, Lauer JA, Hutubessy RC, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 2003;361:717-23.
33. Aziz H, Guvener A, Akhtar SW, et al. Comparative epidemiology of epilepsy in Pakistan and Turkey: population-based studies using identical protocols. Epilepsia 1997;38:716-22.
34. Langfitt JT. Cost-effectiveness of anterotemporal lobectomy in medically intractable complex partial epilepsy. Epilepsia 1997;38:154-63.
35. King JT, Sperling MR, Justice AC, et al. A cost-effectiveness analysis of anterior temporal lobectomy for intractable temporal lobe epilepsy. J Neurosurg 1997;87:20-8.
36. Langfitt J, Wiebe S. Cost-effectiveness of epilepsy therapy: how should treatment effects be measured? Epilepsia 2002;43(suppl 4):17-24.
37. World Health Organization. Epilepsy management at primary health level: protocol for a demonstration project in the People's Republic of China. Geneva: Department of Mental Health and Substance Dependence, WHO, 2000.
38. Heaney DC, Beran RG, Halpern MT. Economics in epilepsy treatment choices: our certain fate? Epilepsia 2002;43(suppl 4):32-8.
39. Scott RA, Lhatoo SD, Sander JWAS. The treatment of epilepsy in developing countries: where do we go from here? Bull WHO 2001;79:344-51.
40. Pal DK, Chaudhury G, Sengupta S, et al. Social integration of children with epilepsy in rural India. Soc Sci Med 2002;54:1867-74.